InstalabLoading...
InstalabLoading...
Most people do not think about antibiotic resistance until a prescription does not work. By then, the question of whether the bacteria in your body were already carrying resistance genes is too late to ask. This stool test answers that question now.
Macrolides are some of the most prescribed antibiotics in the world for sinus infections, bronchitis, sexually transmitted infections, and skin problems. If your gut already harbors microbes carrying genes that disable these drugs, your next course of azithromycin or clarithromycin may do less than you expect, and the resistant bacteria can spread to others.
This is a stool-based test that detects DNA from genes known to make bacteria resistant to macrolide antibiotics. It does not measure a substance your body produces. It looks at the bacteria living in your gut and asks whether any of them carry the genetic instructions to defeat this class of drugs.
The main resistance genes belong to a few families. Some code for enzymes called methyltransferases (the erm gene group) that chemically modify the bacterial ribosome, the cell's protein-building machine, so the antibiotic cannot bind. Others code for efflux pumps (the mef and msr genes) that physically pump the drug out of the cell. A third group codes for enzymes (the mph and ere genes) that chop the antibiotic into harmless pieces.
Because these genes often sit on mobile pieces of DNA that bacteria can swap with each other, the resistance picture in your gut is dynamic. A course of antibiotics, a hospital stay, or even close contact with someone carrying resistant bacteria can change what your microbiome harbors.
Resistance to macrolides is now widespread in the bacterial pathogens that cause common infections. A meta-analysis pooling streptococcal data found resistance to clarithromycin at 57.6% and to azithromycin at 55.8%. A separate meta-analysis on Staphylococcus species reported global macrolide resistance around 53 to 58%, with the highest rates in Oceania.
Resistance in Mycoplasma pneumoniae, a common cause of walking pneumonia, has reached 63% in Asia and as high as 81% in China, while remaining lower in Europe and North America (8.6%). For the sexually transmitted bacterium Mycoplasma genitalium, macrolide resistance commonly runs between 25% and 55% in Russia, Belgium, and US cohorts. These numbers are rising over time.
The bacteria in your gut act as a reservoir. Even when they are not causing infection themselves, they can pass resistance genes to other bacteria, including ones that may later cause illness. They can also be the source of an infection if your immune system is compromised, if you have surgery, or if a routine procedure breaches the gut barrier.
A randomized trial in Kenyan children discharged from the hospital found that macrolide resistance in their gut microbes appeared to influence whether azithromycin actually worked to prevent rehospitalization or death. This is one of the few studies directly linking gut-level resistance to a clinical outcome in humans.
In a Niger trial of mass azithromycin distribution to preschool children, resistance gene carriage rose in the treated group. A secondary analysis looking at untreated older children in the same villages did not find clear spillover, suggesting that gut resistance in any one person reflects largely their own exposures rather than community pressure alone.
Carrying a resistance gene in your gut does not mean you have a current infection. It does not predict whether you will get sick from a resistant organism. It tells you the genetic potential for resistance is present in your microbiome at the time of the sample, which may inform how you and your clinician think about future antibiotic choices, infection workups, and the timing of antibiotic stewardship conversations.
This is also a different test from a clinical susceptibility report. When a doctor cultures bacteria from an infected site (urine, blood, sputum) and tests which antibiotics kill it, that is direct, organism-specific guidance for treating that infection. A gut resistance gene panel is a screening look at your microbiome, not a treatment decision tool for an active infection.
There is no consensus clinical reference range for the carriage of macrolide resistance genes in the gut of healthy adults. This is a research and exploratory marker. Results are typically reported as detected or not detected, sometimes with a relative abundance estimate. Standard susceptibility breakpoints from organizations like EUCAST and CLSI apply to specific bacterial isolates from infected sites, not to mixed gut samples.
These results are illustrative orientation, not a target. Different labs use different gene panels, different DNA sequencing methods, and different reporting cutoffs. Compare your results within the same lab over time for the most meaningful trend.
| Result | What It Suggests |
|---|---|
| Not detected | Genes screened by this assay were not found in your stool sample. Resistance from genes outside the panel cannot be ruled out. |
| Detected (low abundance) | Resistance genes are present in a small fraction of your gut bacteria. The clinical meaning of low-level carriage in healthy people is still being studied. |
| Detected (higher abundance) | Resistance genes are well represented in your microbiome. This pattern is more common after recent antibiotic exposure or hospitalization. |
Your gut microbiome shifts with diet, travel, illness, and especially antibiotic use. A single snapshot tells you what is there now, not what your baseline looks like or how quickly resistance genes appear and fade. Tracking the result over time turns a static finding into useful information.
A reasonable cadence is a baseline test, a follow-up 3 to 6 months later if you have taken antibiotics or made significant changes, and at least annually thereafter. If you have a course of macrolides for any reason, retesting 1 to 3 months afterward can show whether the resistance gene burden in your gut has shifted.
A positive result is not a diagnosis and does not require treatment by itself. There is no antibiotic regimen designed to clear resistance genes from a healthy gut. The decision pathway is about awareness and stewardship, not eradication.
Practical next steps include sharing the result with any clinician prescribing you antibiotics, especially for respiratory or sexually transmitted infections where macrolides are first-line. Pair the result with a broader gut workup if you have ongoing digestive symptoms, including markers of gut inflammation and a microbiome composition test. If you have recurrent infections, consider asking for culture and susceptibility testing on the actual infected site rather than empirical antibiotic prescriptions.
Evidence-backed interventions that affect your Macrolides Resistance level
Macrolides Resistance is best interpreted alongside these tests.